UY37133A - Derivados de pirazolo[1,5-a]pirazin-4-ilo - Google Patents

Derivados de pirazolo[1,5-a]pirazin-4-ilo

Info

Publication number
UY37133A
UY37133A UY0001037133A UY37133A UY37133A UY 37133 A UY37133 A UY 37133A UY 0001037133 A UY0001037133 A UY 0001037133A UY 37133 A UY37133 A UY 37133A UY 37133 A UY37133 A UY 37133A
Authority
UY
Uruguay
Prior art keywords
pirazin
pirazolo
ilo
derivatives
combinations
Prior art date
Application number
UY0001037133A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Frank Brown
Alpay DERMENCI
Andrew Fensome
Brian Stephen Gerstenberger
Matthew Merrill Hayward
Dafydd Rhys Owen
Stephen Wayne Wright
Li Huang Xing
Xiaojing Yang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY37133A publication Critical patent/UY37133A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
UY0001037133A 2016-02-24 2017-02-22 Derivados de pirazolo[1,5-a]pirazin-4-ilo UY37133A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662299130P 2016-02-24 2016-02-24

Publications (1)

Publication Number Publication Date
UY37133A true UY37133A (es) 2017-09-29

Family

ID=58054385

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037133A UY37133A (es) 2016-02-24 2017-02-22 Derivados de pirazolo[1,5-a]pirazin-4-ilo

Country Status (45)

Country Link
US (4) US10144738B2 (zh)
EP (2) EP3712153B1 (zh)
JP (1) JP6505956B2 (zh)
KR (1) KR102128671B1 (zh)
CN (1) CN109071546B (zh)
AR (1) AR107714A1 (zh)
AU (1) AU2017222417B2 (zh)
CA (1) CA2958490C (zh)
CL (1) CL2018002358A1 (zh)
CO (1) CO2018008799A2 (zh)
CR (1) CR20180372A (zh)
CU (1) CU24511B1 (zh)
CY (1) CY1122949T1 (zh)
DK (1) DK3419978T3 (zh)
DO (1) DOP2018000187A (zh)
EA (1) EA035036B1 (zh)
EC (1) ECSP18072109A (zh)
ES (1) ES2794779T3 (zh)
GE (1) GEP20217242B (zh)
HK (1) HK1258157A1 (zh)
HR (1) HRP20200781T1 (zh)
HU (1) HUE049305T2 (zh)
IL (1) IL260923B (zh)
LT (1) LT3419978T (zh)
MA (2) MA52987A (zh)
MD (1) MD3419978T2 (zh)
ME (1) ME03743B (zh)
MX (1) MX2018010236A (zh)
MY (1) MY189118A (zh)
NI (1) NI201800080A (zh)
NZ (1) NZ744349A (zh)
PH (1) PH12018501788A1 (zh)
PL (1) PL3419978T3 (zh)
PT (1) PT3419978T (zh)
RS (1) RS60261B1 (zh)
RU (1) RU2718902C2 (zh)
SG (1) SG11201806307YA (zh)
SI (1) SI3419978T1 (zh)
SV (1) SV2018005726A (zh)
TN (1) TN2018000295A1 (zh)
TW (1) TWI665201B (zh)
UA (1) UA119835C2 (zh)
UY (1) UY37133A (zh)
WO (1) WO2017144995A1 (zh)
ZA (1) ZA201804972B (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3419978T (pt) 2016-02-24 2020-06-01 Pfizer Derivados de pirazolo[1,5-a]pirazin-4-ilo como inibidores de jak
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
UY38144A (es) 2018-03-12 2019-10-31 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa
CN112469412A (zh) 2018-05-17 2021-03-09 拜耳公司 取代的二氢吡唑并吡嗪甲酰胺衍生物
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
KR20210049090A (ko) 2018-07-05 2021-05-04 인사이트 코포레이션 A2a/a2b 억제제로서 융합된 피라진 유도체
AR116592A1 (es) 2018-10-17 2021-05-26 Lilly Co Eli Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
AU2020256720B2 (en) * 2019-04-12 2022-09-01 PrimeGene (Beijing) Co. Ltd. Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof
CA3138473A1 (en) 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
EP4028007A1 (en) * 2019-09-11 2022-07-20 Pfizer Inc. Treatment of hidradenitis with jak inhibitors
TW202135816A (zh) * 2019-12-18 2021-10-01 美商輝瑞股份有限公司 以激酶抑制劑治療潰瘍性結腸炎
AU2021248720A1 (en) 2020-04-04 2022-11-03 Pfizer Inc. Methods of treating coronavirus disease 2019
US20230159539A1 (en) * 2020-04-08 2023-05-25 Pfizer Inc. Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
AU2021339756A1 (en) * 2020-09-11 2023-04-13 Pulmosim Therapeutics Llc Compositions and methods for treating or preventing pulmonary hypertension
CN112592345B (zh) * 2020-12-07 2024-09-13 嘉兴特科罗生物科技有限公司 一种三氮唑并吡嗪类化合物及其用途
WO2022165530A1 (en) * 2021-02-01 2022-08-04 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
US20240156822A1 (en) 2021-03-30 2024-05-16 Pfizer Inc. Methods For Treatment of Vitiligo
CA3236262A1 (en) 2021-10-25 2023-05-04 Isaac Marx Tyk2 degraders and uses thereof
EP4431510A1 (en) * 2021-11-12 2024-09-18 Soter Biopharma Pte. Ltd. Pyrazolo fused ring compound and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5442448B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド Ｆｇｆｒインヒビターとしての二環式ヘテロ環式化合物
AR066879A1 (es) * 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
PE20110223A1 (es) 2008-06-10 2011-05-07 Abbvie Inc DERIVADOS DE PIRROLO[2,3-e][1,2,4]TRIAZOLO[4,3-a]PIRAZIN, COMO INHIBIDORES DE QUINASA
ATE542813T1 (de) 2008-08-06 2012-02-15 Pfizer 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
WO2010117787A2 (en) 2009-03-30 2010-10-14 The Brigham And Women's Hospital, Inc. Inhibiting eph b-3 kinase
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
EP2558468B1 (en) * 2010-04-14 2015-04-01 Array Biopharma, Inc. 5, 7-substituted-imidazo [1,2-c] pyrimidines as inhibitors of jak kinases
EP2397482A1 (en) 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
CA2851623A1 (en) 2011-10-12 2013-04-18 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
JPWO2013146963A1 (ja) * 2012-03-28 2015-12-14 武田薬品工業株式会社 複素環化合物
CN104169284B (zh) 2012-03-28 2017-03-29 默克专利股份公司 双环吡嗪酮衍生物
US9376441B2 (en) 2013-07-31 2016-06-28 Gilead Sciences, Inc. Substituted pyrrolidines as SYK inhibitors
TW201605811A (zh) 2013-12-11 2016-02-16 阿爾米雷爾有限公司 作為jak抑制劑之吡唑并嘧啶-2基衍生物
WO2015166370A1 (en) * 2014-04-28 2015-11-05 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
WO2016009028A1 (fr) 2014-07-17 2016-01-21 Valeo Systèmes d'Essuyage Balai plat caréné d'essuie-glace
EP3227297B1 (en) * 2014-12-05 2021-01-20 Array Biopharma, Inc. 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
TW201639845A (zh) 2015-01-29 2016-11-16 和記黃埔醫藥（上海）有限公司 新的雜芳基和雜環化合物、其組成物及方法
CA2976109A1 (en) 2015-02-13 2016-08-18 Dana-Farber Cancer Institute, Inc. Substituted pyrrolopyrimidine, pyrazolopyrimidine and purine derivatives and use thereof as lrrk2 inhibitors
GB201504565D0 (en) 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
AU2016254385B2 (en) 2015-04-29 2018-05-10 Wuxi Fortune Pharmaceutical Co., Ltd JAK inhibitors
CN108473498B (zh) 2015-12-22 2021-11-02 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
PT3419978T (pt) 2016-02-24 2020-06-01 Pfizer Derivados de pirazolo[1,5-a]pirazin-4-ilo como inibidores de jak
AU2017395023B2 (en) 2016-12-23 2022-04-07 Plexxikon Inc. Compounds and methods for CDK8 modulation and indications therefor
ES2948194T3 (es) 2017-01-18 2023-09-01 Array Biopharma Inc Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET
CN110785418A (zh) 2017-06-21 2020-02-11 豪夫迈·罗氏有限公司 作为irak4调节剂的异二氢吲哚酮衍生物
EP3668858A1 (en) 2017-08-14 2020-06-24 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives

Also Published As

Publication number Publication date
CA2958490A1 (en) 2017-08-24
CL2018002358A1 (es) 2018-11-30
MA43668B1 (fr) 2020-05-29
AU2017222417A1 (en) 2018-08-02
CU20180078A7 (es) 2019-02-04
WO2017144995A1 (en) 2017-08-31
RS60261B1 (sr) 2020-06-30
NZ744349A (en) 2023-06-30
AU2017222417B2 (en) 2020-07-09
SG11201806307YA (en) 2018-09-27
EP3419978B1 (en) 2020-04-15
US20190071448A1 (en) 2019-03-07
US20170240552A1 (en) 2017-08-24
DOP2018000187A (es) 2019-01-31
PH12018501788A1 (en) 2019-06-17
EP3712153A1 (en) 2020-09-23
KR102128671B1 (ko) 2020-06-30
US20230045252A1 (en) 2023-02-09
MA52987A (fr) 2021-04-28
HRP20200781T1 (hr) 2020-07-24
MX2018010236A (es) 2019-01-14
BR112018015501A2 (pt) 2018-12-18
RU2018130547A (ru) 2020-03-25
ME03743B (me) 2021-04-20
CO2018008799A2 (es) 2018-09-20
SI3419978T1 (sl) 2020-08-31
CR20180372A (es) 2018-09-19
RU2718902C2 (ru) 2020-04-15
CA2958490C (en) 2024-02-27
EA201891463A1 (ru) 2019-03-29
HK1258157A1 (zh) 2019-11-08
ECSP18072109A (es) 2018-10-31
RU2018130547A3 (zh) 2020-03-25
CN109071546B (zh) 2021-03-02
US10144738B2 (en) 2018-12-04
ZA201804972B (en) 2019-06-26
US10822341B2 (en) 2020-11-03
US11472809B2 (en) 2022-10-18
HUE049305T2 (hu) 2020-09-28
MY189118A (en) 2022-01-26
IL260923B (en) 2022-01-01
EP3712153B1 (en) 2021-12-01
AR107714A1 (es) 2018-05-23
KR20180103158A (ko) 2018-09-18
PL3419978T3 (pl) 2020-11-30
CN109071546A (zh) 2018-12-21
ES2794779T3 (es) 2020-11-19
CY1122949T1 (el) 2021-10-29
UA119835C2 (uk) 2019-08-12
EP3419978A1 (en) 2019-01-02
MD3419978T2 (ro) 2020-07-31
PT3419978T (pt) 2020-06-01
TN2018000295A1 (en) 2020-01-16
JP2019510003A (ja) 2019-04-11
EA035036B1 (ru) 2020-04-20
NI201800080A (es) 2018-11-22
GEP20217242B (en) 2021-04-12
LT3419978T (lt) 2020-06-10
CU24511B1 (es) 2021-05-12
TWI665201B (zh) 2019-07-11
DK3419978T3 (da) 2020-06-02
JP6505956B2 (ja) 2019-04-24
SV2018005726A (es) 2018-10-24
US20200399281A1 (en) 2020-12-24
TW201741313A (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
UY37133A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
CO2021007230A2 (es) Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
CL2019003669A1 (es) Inhibidores de quinasa alk2 que contienen imidazol.
BR112017024933A8 (pt) Alvocidib produce com a bioavailabilidade aumentada
EA201792116A1 (ru) Ингибитор янус-киназы
AR058780A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
CR20190236A (es) Compuestos terapéuticos y métodos para utilizarlos
AR063097A1 (es) Pirazolopirimidinas[1,5-a] inhibidoras de quinasas dependientes de ciclina(cdk), composiciones farmaceuticas que las contienen y usos en el tratamiento de enfermedades proliferativas
UY37941A (es) Derivados de bencimidazol y sus usos
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112021011325A2 (pt) Derivados de rapamicina
MY194711A (en) Novel annelated phenoxyacetamides
AR101806A1 (es) Derivados de 1-acetil-4-amino-1,2,3,4-tetrahidroquinolina, composición farmacéutica que los comprende y su uso en el tratamiento de afecciones mediadas por un inhibidor de bromodominio
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
EA202190064A1 (ru) Цианотриазоловые соединения и варианты их применения
UY38006A (es) Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones
BR112019007631A2 (pt) inibidores de bromodomínios
BR112016023991A2 (pt) ativadores de herg policíclicos
EA201792676A1 (ru) Ингибиторы jak1
UY39308A (es) Derivados de aminopirimidinilo
AR045248A1 (es) Oxazoles, su fabricacion y uso como agentes farmaceuticos
AR114263A1 (es) Compuestos terapéuticos y métodos para utilizarlos